Saturday 17 October 2026 Export SOPH’s income statement to Excel — free account

SOPHiA GENETICS SA

SOPH Healthcare Health Information Services

SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

6.73 0.56 −7.68%

Follow SOPH

Alert me

Market cap: $620.6M
P/E: 0.0×
Fwd P/E: −5.5×
Dividend yield: —
F-score: 2/9
Altman Z: −3.43
Beneish M: −3.30
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Total sells 5.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	—	—	—
Sell	—	—	—	—	9	33	12	9	14	14	7	12

Insider Ownership 16.36%

Capital & Financial Ratios $m

Market Cap 620.58

Revenue 86.17

Net Income (80.30)

Free Cash Flow (41.21)

Net Debt (59.67)

Current Ratio 2.69

Debt/Equity 0.58

P/E ratio 0.00

Fwd P/E (5.51)

P/S ratio 5.77

P/B ratio 5.98

Past 5Y EPS Growth —

This Y EPS Growth 19.83%

Next Y EPS Growth 33.26%

Next Y revenue growth 23.24%

Next 5Y EPS Growth 32.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.29%

10-year low 10-year high

P/B against its own 10 years 83.27%

10-year low 10-year high

EV/Sales against its own 10 years 80.66%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	123	80	70	108
Receivables	14	7	15	14
Inventory	6	6	6	7
Other	5	6	7	8
	148	99	99	137

	2023	2024	2025	Q'26
Payables	5	5	9	12
ST’ Debt	—	—	—	—
Other	—	0	1	2
	36	27	51	51

Compound Annual Growth %

	10y	5y	3y
Sales	—	22.16%	17.56%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(14.05%)	(38.24%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	22	23	—	—	—
’25	18	18	19	22	77
’24	16	16	16	18	65
’23	14	15	16	17	62
’22	11	12	12	13	48
’21	9	10	10	11	40
’20	7	6	7	8	28

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(8)	—	—	—
’25	(11)	(8)	(9)	(8)	(36)
’24	(15)	(10)	(9)	(11)	(45)
’23	(15)	(10)	(12)	(11)	(49)
’22	(17)	(20)	(23)	(10)	(70)
’21	(10)	(16)	(16)	(15)	(58)
’20	(7)	(5)	(10)	(9)	(32)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(8)	—	—	—
’25	(11)	(8)	(9)	(8)	(37)
’24	(15)	(11)	(9)	(11)	(45)
’23	(16)	(12)	(13)	(11)	(50)
’22	(18)	(21)	(24)	(11)	(75)
’21	(10)	(17)	(18)	(16)	(61)
’20	(7)	(5)	(11)	(10)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.27)	(0.30)	—	—	—
’25	(0.26)	(0.33)	(0.30)	(0.28)	(1.17)
’24	(0.21)	(0.23)	(0.28)	(0.23)	(0.95)
’23	(0.31)	(0.33)	(0.21)	(0.37)	(1.22)
’22	(0.40)	(0.39)	(0.36)	(0.22)	(1.36)
’21	(0.26)	(0.38)	(0.35)	(0.33)	(1.33)
’20	(0.27)	(0.20)	(0.24)	(0.22)	(0.93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	11.71	1.69	1.85	2.70	2.58	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	19.80	15.83	5.77	7.37	5.30
People
People	Employees	—	—	—	—	462	518	466	449	423	415
	Revenue/emp, $m	—	—	—	0.00	0.06	0.08	0.10	0.14	0.15	0.19
Income, $m
Income, $m	Revenue	—	—	—	25	28	40	48	62	65	77
	Gross margin, %	—	—	—	70.30	62.29	62.35	65.71	68.80	67.42	67.40
	EBT	—	—	—	(34)	(41)	(74)	(88)	(78)	(61)	(77)
	EBT margin, %	—	—	—	(132.60)	(145.16)	(181.72)	(184.16)	(125.85)	(94.01)	(100.28)
	Net income	—	0	—	(34)	(41)	(74)	(88)	(78)	(61)	(77)
	Depreciation	—	—	—	2	2	4	6	8	9	10
Per share, $
Per share, $	Revenue	—	—	—	0.67	0.67	0.73	0.74	0.96	0.99	1.14
	Earnings	—	—	—	(0.90)	(0.93)	(1.33)	(1.36)	(1.22)	(0.95)	(1.17)
	Cash flow	—	—	—	(0.84)	(0.75)	(1.05)	(1.09)	(0.75)	(0.67)	(0.53)
	Capex	—	—	—	(0.08)	(0.02)	(0.05)	(0.07)	(0.03)	(0.01)	(0.01)
	Free cash flow	—	—	—	(0.92)	(0.77)	(1.10)	(1.16)	(0.78)	(0.68)	(0.54)
	Book value	—	—	—	0.59	2.37	4.98	3.12	2.34	1.46	0.70
	Shares, m	—	—	—	38	42	55	64	65	66	68
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	24.00	24.00	19.28	3.03	5.01	3.11	4.08
	P/B	—	—	—	11.53	11.53	2.83	0.72	2.07	2.10	6.69
	EV/Sales	—	—	—	22.24	22.24	13.04	(0.39)	3.30	2.11	3.81
	EV/FCF	—	—	—	(15.91)	(15.91)	(8.68)	0.25	(4.09)	(3.06)	(8.04)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(32)	(32)	(58)	(70)	(49)	(45)	(36)
	Capex	—	—	—	(3)	(1)	(3)	(5)	(2)	0	(1)
	Free cash flow	—	—	—	(35)	(32)	(61)	(75)	(50)	(45)	(37)
Balance, $m
Balance, $m	Working capital	—	—	—	15	88	254	169	112	73	49
	Total debt	—	—	—	4	3	11	14	—	13	48
	Net debt	—	—	—	(15)	(94)	(254)	(165)	(123)	(67)	(23)
	Shareholders’ equity	—	—	—	22	101	275	200	151	96	47
Returns, %
Returns, %	ROA	—	—	—	(130.83)	(42.81)	(32.58)	(31.01)	(35.10)	(34.58)	(49.63)
	ROIC	—	—	—	(263.58)	(359.77)	(209.50)	(154.31)	(165.89)	(141.03)	(180.23)
	ROE	—	—	—	(55.05)	(64.09)	(39.20)	(36.78)	(44.93)	(50.41)	(110.00)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HSTM HealthStream, Inc.	$1.0B	46.0×	34.4×	+12.55% (above 0%: growing)	+27.78% (above 0%: growing)	+362.71% (above 0%: growing)	65.35%	9.94%	Compare
PHR Phreesia, Inc.	$685.3M	64.4×	23.5×	+10.41% (above 0%: growing)	+200.00% (above 0%: growing)	+43.51% (above 0%: growing)	66.64%	5.88%	Compare
MDRX Veradigm Inc.	$654.5M	— (loss-making)	— (loss-making)	−9.74% (below 0%: shrinking)	n/m	−66.33% (below 0%: shrinking)	50.53%	(37.41%)	Compare
SOPH SOPHiA GENETICS SA	$620.6M	— (loss-making)	— (loss-making)	+27.22% (above 0%: growing)	n/m	+6.50% (above 0%: growing)	64.61%	(86.03%)
WEAV Weave Communications, Inc.	$594.5M	— (loss-making)	— (loss-making)	+15.52% (above 0%: growing)	n/m	+94.33% (above 0%: growing)	72.03%	(6.49%)	Compare
EVH Evolent Health, Inc	$550.6M	— (loss-making)	— (loss-making)	+46.86% (above 0%: growing)	n/m	+58.67% (above 0%: growing)	12.39%	(1.47%)	Compare
NRC National Research Corporation	$466.9M	80.6×	4.9×	+3.98% (above 0%: growing)	n/m	+101.49% (above 0%: growing)	61.67%	(9.15%)	Compare
CTEV Claritev Corporation	$404.4M	— (loss-making)	— (loss-making)	+6.59% (above 0%: growing)	n/m	+49.10% (above 0%: growing)	73.72%	9.09%	Compare
CARL Carlsmed, Inc.	$380.9M	— (loss-making)	— (loss-making)	+56.75% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.78%	(58.27%)	Compare
Median of peers	$572.6M	64.4×	23.5×	+11.48%	—	+53.89%	66.00%	(3.98%)

All 51 Health Information Services stocks →

SOPHiA GENETICS SA (SOPH) key facts

Strength: SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024.
SOPHiA GENETICS SA (SOPH) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SOPH traded at $6.73, a market capitalization of $620.6 million.
Return on equity was −110.0% and debt-to-equity 0.58.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −3.43 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.